A single-dose oral toxicity study was conducted to examine the qualitative and quantitative toxicity of a commercial-grade batch of dihydrocapsiate (4-hydroxy-3-methoxybenzyl 8-methylnonanoate; CAS No. 205687-03-2). Dihydrocapsiate was administered once by gavage to ICR mice at dose levels of 0 (vehicle) or 5000 mglkglday. No mortality was observed during the 14 day observation period following test article administration. During the 2 h immediately following dosing, mice of both sexes treated with dihydrocapsiate were observed to exhibit one or more of the following: staggered gait, decreased spontaneous movement, increased time in the prone position, tremors, gasping, or red-brownish urine. All mice had completely recovered by the 6 h observation interval. No effects on body weights or necropsy findings were observed as a result of dihydrocapsiate administration. These results suggested that the lethal dose of dihydrocapsiate was >5000 mgikg. In an in vivo micronucleus test using 8DF 1 male mice, a commercial grade of dihydrocapsiate neither increased the incidence of micronucleated polychromatic erythrocytes (MNPCEs) nor decreased the ratio of polychromatic erythrocytes (PCEs) in any ofthe treatment groups. The results suggest that commercial-grade dihydrocapsiate is unlikely to be an in vivoclastogen.
). Kobata et al, (1998 Kobata et al, ( , 1999 determined the structures of capsinoids and named capsiate (4-hydroxy-3-methoxybenzyl (E)-8-methyl-6-nonenoate), dihydrocapsiate (4-hydroxy-3methoxybenzyl 8-methylnonanoate; Figure 1) , and nordihydrocapsiate (4-hydroxy-3-methoxybenzyl 7-rnethyloctanoate), respectively. Capsinoids have an ester bond instead of the amide bond between the vanillyl moiety and fatty acid chain normally found in capsaicin.
Capsaicin produces a variety of well-documented physiological effects. However, the commercial utility of the compound is limited due its strong pungency, which restricts the quantities of capsaicin that can be added to food and medicine. In contrast, capsinoids are nonpungent, making it possible to utilize larger quantities of capsinoids in food applications without the attendant heat effect found in capsaicin. The replacement of the amide bond with an ester bond (joining the vanillyl moiety and the fatty acid chain) is the basis for this pharmacological change.
Although capsinoids occur naturally in various cultivars of capsicum pepper, comparatively small amounts of capsinoids, as compared to capsaicinoids, are contained in capsicum cultivars. Yazawa et al. (2004) reported an exception to this in CH 19 Sweet. Working on the issue of availability, Kobata et· al. (2002) reported a method of synthesizing capsinoids through an enzymatic process involving vanillyl alcohol and fatty acid. Using these methods, Ajinomoto Co., Inc. developed a synthetic process for producing dihydrocapsiate (unpublished) . With the increase in availability, dihydrocapsiate could provide an alternative source of capsinoids for use as a food ingredient.
Capsaicinoid Safety
A number of safety studies have been performed on capsaicin and capsaicin-containing mixtures and the results are reported FIGURE I Chemical structure ofdihydrocapsiate.
in the public literature. Gavage LD 50 values of capsaicin were 97.0 to 118.8 mg/kg and 148.1 to 161.2 mg/kg in mice and rats, respectively. With regard to necropsy findings in those acute studies, no changes were observed in mice that survived until termination; whereas in those that died during the observation period, erosion and ulceration of gastric fundus were identified (Saito and Yamamoto 1996) . For genotoxicity, capsaicin and chili extracts were mutagenic, with metabolic activation in the reverse-mutation test. In the micronucleus test in mice, capsaicin was positive at a dose close to the intraperitoneal LD 50 value (7.6 rug/kg) (Nagabhushan and Bhide 1985) . Watanabe et al. (2008b) evaluated the acute toxicity of CH-19 Sweet extract by administering a single gavage dose at levels of 0 (vehicle), 5, 10, or 20 ml/kg body weight (BW) (equivalent to 356.25, 712.5, and 1425 mg/kg BW of capsinoids, respectively). The only toxicity observed was on the day of administration (transient salivation or decreased spontaneous movement) at :::10 ml/kg BW. As no deaths occurred, the LD 50 was> 20 ml/kg of CH 19 Sweet extract (1425 mg/kg as capsinoids) for both males and females. In the same study, Watanabe et al. (2008b) reported on the results of a series of mutagenicity tests that included a bacterial reversemutation test, an in vitro chromosome aberration test, and an in vivo micronucleus test. The results suggested the absence of mutagenicity as well as in vitro and in vivo c1astogenicity of CH 19 Sweet extract or the capsinoids contained therein.
Capsinoid Safety

Dihydrocapsiate Safety
All of the above studies evaluated dihydrocapsiate as a component of a mixture. Bernard et al. (2008b) performed a series of genotoxicity studies using dihydrocapsiate as the test article itself rather than as a component of a complex mixture. That study employed a variety of in vitro and in vivo test systems, including bacterial reverse-mutation test, chromosomal aberration test, micronucleus test, gene mutation assay with transgenic rats (Big Blue), and single-cell gel (SCG) assay (Comet assay). Dihydrocapsiate was found to be to be nonmutagenic in the mouse micronucleus tests and the gene mutation test with transgenic rats. In the bacterial reverse-mutation test and chromosomal aberration test, dihydrocapsiate demonstrated positive results without metabolic activity and negative results with metabolic activity. The single-cell gel (SCG) assay results were equivocal.
Study Rationale
Previous micronucleus testing (Bernard et al. 2008b ) was performed on dihydrocapsiate produced on a laboratory scale. In order to scale up for commercial production of dihydrocapsiate, two steps were modified, which resulted in minor changes to the impurity profile. Most of the levels of impurities detected in the original process decreased in the modified process, three new impurities were detected and quantitated at <0.025%, 0.07%, and 0.42%, and three of the original impurities were slightly increased (i.e., to 0.06%, 0.015%, and 0.02%). Based upon these findings, it was decided to perform an additional micronucleus test in mice using dihydrocapsiate produced in the modified (commercial) process.
Furthermore, although several multiple-dose studies had been performed on dihydrocapsiate, (Bernard et al. 2008a; Kodama et al. 2008) , no acute toxicity data were available.
Thus, it was decided to obtain information on this toxicological parameter at this time.
The single-dose toxicity study was conducted at Ajinomoto Co., Inc. (Tokyo, Japan). The genotoxicity studies were performed at the Biosafety Research Center, Foods, Drugs and Pesticides (Shizuoka, Japan). Both of these studies were conducted in compliance with the Law Concerning the Protection 
MATERIALS AND METHODS
The Test Substance
The test substance, dihydrocapsiate, a viscous, colorless to yellow liquid supplied by Ajinomoto Co., Inc. (Tokyo, Japan; lot no. 060807), contained 4.3% of 8-methylenonanoic acid, the acyl residue of dihydrocapsiate. The test article purity (94.0%) was maintained by protecting the compound from heat and light by storing it in a freezer throughout the study.
The vehicle, medium-chain triglyceride (MCT; product name: Actor M-2), was manufactured by Riken Vitamin Co., Ltd. (Tokyo, Japan).
Single-Dose Toxicity Study
Mice and Animal Hushandry
Twelve male and 12 female ICR mice (Crj:CD-l(lCR); Atsugi Breeding Center, Charles River Japan, Inc., Kanagawa, Japan) were purchased at 4 weeks of age and quarantined/acclimated to the animal room for l4-days. During this period, the mice were observed once daily for clinical signs such as external appearance, nutritional condition, and behavior. The mice were weighed three times during this period. Based on the results of clinical observation, body weight gain and body weight at the time of grouping, 10 male and 10 female healthy mice, 6 weeks of age, were selected to be subjects for the study. The mice were rank ordered based on body weight on the day of grouping and assigned to groups (five mice/sex/group) in such a way that group mean body weights were comparable. Mice remaining after grouping were removed from the study on the following day. Individual body weights on the day of administration were 27.2 to 32.2 g and 19.2 to 23.6 g for males and females, respectively. Mice were housed in an animal room in which the temperature was maintained at 23±3°C, the relative humidity at 50±20%, the air ventilation at 10 to 15 changes per hour, and the illumination for 12 hours a day (07:00 to 19:00 h). Mice were housed five to a polycarbonate cage (W 215 x D 320 x H 130 mm; CREA Japan, Inc.) with bedding (Whiteflake; Charles River Japan, Inc.). The mice were allowed free access to pelleted diet CRF-I (radiationsterilized; Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water.
Dosage Preparation
In accordance with the Redbook 2000, 5000 mg/kg/day, was selected as the dose level and, as the oral route is the intended human exposure route, gavage was selected as the route of administration. The test substance was dissolved in the vehicle (MCT) and administered once by gavage using metallic feeding tubes at a volume of 5 ml/kg body weight (BW). Mice in the control group received the vehicle alone in the same manner.
Observations and Necropsy
Mice were observed for clinical signs such as external appearance, nutritional condition, posture, behavior, and appearance of excreta beginning immediately after dosing and intermittently for a period of 5 min thereafter. Subsequently, mice were observed at 15 and 30 min, 1,2, and 6 h, and once daily thereafter for 14-days. Mice were weighed several times during the observation period. At the end of the 14-day observation period, mice were sacrificed by exsanguination under ether anesthesia, and external appearance and organs/ tissues in the cephalic, thoracic, and abdominal regions were observed macroscopically and recorded.
For the analysis of body weights, the group means with standard deviations were calculated and each group was analyzed for homogeneity of variance (level of significance: 5%, two-tailed) Using the F test (JIS 1965) . Because the variances were homogeneous, the group mean difference between the control group and dihydrocapsiate dose group was analyzed by the Student's t test (p < .05, two tailed; JIS 1965).
Micronucleus Test Experimental Procedures
Thirty-eight male BDF, strain SPF mice (Japan SLC. Inc.. Shizuoka, Japan) were purchased at 8 weeks of age. After 6 days of quarantine, healthy mice were randomly assigned to groups (six mice/group) using a stratified body weight procedure. Unassigned mice were euthanized by CO 2 inhalation. Individual body weights on the day of grouping were 24.2 to 29.0 g. Based on the results of the dose-finding study. 2000 mg/kg was selected as the high-dose level, and two lower doses (1000 and 500 mg/kg) were included. As the intended route of exposure for humans is oral, the vehicle and test article were administered by gavage in a volume of 5 ml/kg BW.
The test substance was dissolved in the vehicle (MCT) and administered using flexible stomach tubes once daily at a 24h interval for 2 consecutive days. The positive-control substance (mitomycin C [MMC]; Kyowa Hakko Kogyo Co., Ltd. Tokyo. Japan) was administered by a single intraperitoneal injection (0.5 rng/kg BW). Mice were euthanized by CO 2 inhalation 24 h after the final administration. One femur was removed and the bone marrow cells were flushed into a centrifuge tube with fetal bovine serum (Invitrogen Japan K.K., Tokyo, Japan; inactivated at 56°C for 30 min). Centrifugation was employed to remove excess serum and the resultant material was used to prepare three bone marrow smear slides/animal. The first slide was employed to evaluate the preparation of the smear slide and the remaining two slides were employed for microscopic observation. Following drying, these slides were fixed using methanol.
To facilitate microscopic examination, two smear slides from each mouse were stained with 3% Giemsa solution (Merck Ltd., Tokyo, Japan) for 30 min, followed by a rinse with 1/100 mol/L sodium phosphate buffer (Merck Ltd.; buffer tablets pH 6.8) and purified water. After air drying, the smear slides were rinsed with 0.00 I% citric acid solution and purified water and again permitted to dry again. Bone marrow smears were prepared from all mice and coded. Slides from live mice/group were chosen in a blinded manner and examined for abnormalities, The incidence (%) of micronucleated polychromatic erythrocytes (MNPCEs) was calculated based on the observation of 2000 polychromatic erythrocytes (PCEs) per mouse. To investigate the effect on bone marrow cell proliferation, the ratio (%) of PCEs to 500 erythrocytes was calculated. The conditional binomial test was conducted to compare the incidences or'MNPCEs between the negative-control group and each treatment group or positive-control group (Kastenbaum and Bowman 1970) . The ratios of PCEs for all groups were analyzed statistically for homogeneity of variance using Bartlett's test (Sokal and Rohlf 1969) . Because the variances were homogeneous, Dunnett's multiple comparison test was conducted (Dunnett 1964) . The data from the negative-control group were compared with those from the positive-control group by the F test for homogeneity of variance between each of the two groups (JIS 1965) . Because the variances were homogeneous, Student's t test (JIS 1965) was conducted. The results were evaluated as positive when the incidences of MNPCEs in the treatment groups were significantly different from those in the negative-control group.
RESULTS
Single-Dose Toxicity Study
No deaths occurred during the observation period. Acute toxic symptoms were observed for 2 h following test article administration. Staggered gait, decreased spontaneous movement, lying in the prone position, tremor, gasping, or red-brownish urine were noted in males or females in the dihydrocapsiate group; all of which resolved by 6 hours after administration. From day 2 to the necropsy (day 15), no abnormal general symptoms were observed in the treatment group. No significant differences in mean body weight between the control group and dihydrocapsiate group were observed both in males and females (data not shown). Administration of dihydrocapsiate had no effect on the necropsy findings.
Micronucleus Test
In clinical observations after dosing, there were no toxic signs in the animals in the dihydrocapsiate groups. The results of the micronucleus test are presented in Table I . In the negativecontrol group, there were 0 to 5 micronucleated cells (MNPCEs) in 2000 polychromatic erythrocytes per mouse and the incidence ofMNPCEs was 0.14%. The ratio of polychromatic erythrocytes to the total number of analyzed erythrocytes (ratio of PCEs) was 54.8%. The incidences of MNPCEs after the administration of the test substance were 0.19% in the 500 mg/kg group, 0.17% in the 1000 mg/kg group, and 0.13% in the 2000 mg/kg group. No statistically significant increases were noted in any of the treatment groups compared with the negative-control group. The ratios of PCEs, an index of the effect of the test substance on the bone marrow cells, were 60.8%, 59.0%, and 60.2% in the 500, 1000, and 2000 mg/kg groups, respectively. No statistically significant differences were noted in any of the treatment groups compared with the negative-control group. On the other hand, the incidence of MNPCEs in the positive-control group markedly increased to 1.22% (19 to 30 MNPCEs in 2000 PCEs). and this increase was statistically significant (p ::: .025) compared with the negative-control group. The ratio of PCEs was 58.8%.
DISCUSSION
In order to perform the qualitative assessment of single oral dose toxicity of commercial-grade dihydrocapsiate in mice, the compound was administered as a single gavage dose of o (vehicle control) or 5000 mg/kg to 6 week old ICR mice, five/sex/group. The vehicle-control group received Actor M2 in an identical manner.
No deaths occurred during the observation period, leading to the conclusion that the lethal dose of commercial-grade dihydrocapsiate was >5000 mg/kg. Acute signs of toxicity were observed in both sexes for up to 2 h following dosing and included staggered gait, decreased spontaneous movement, lying in a prone position, prone position, tremor, gasping, or redbrownish urine. Analyses of body weight measurements and necropsy findings failed to detect any lasting effect of dihydrocapsiate administration.
An in vivo micronucleus test using BDF, male mice was employed to determine the ability of commercial-grade dihydrocapsiate to induce MNPCEs of capsinoids. No statistically significant increases in the incidence of were observed in any treated groups up to 2000 mg/kg compared with the negativecontrol group. No statistically significant decreases in the ratio of PCEs were observed in any of the treatment groups. This finding is consistent with that previously reported by Bernard et aI. (2008b) in which an in vivo evaluation of commercialgrade dihydrocapsiate in a gene mutation assay in transgenic rats resulted in negative findings.
That same publication (Bernard et al. 2008b ) evaluated the potential genotoxicity of dihydrocapsiate produced in the initial manufacturing process. The tests employed included the in vivo micronucleus test in BDF, male mice, the same one described in the study reported herein, as well as the bacterial reversemutation assay, Chinese hamster lung chromosome aberration test, and the single-cell gel (SCQ) assay in rats (Comet assay). Dihydrocapsiate was found to be nonmutagenic in the mouse micronucleus tests and the gene mutation test with transgenic rats. In the bacterial reverse-mutation test and the chromosomal aberration test, dihydrocapsiate demonstrated positive results without metabolic activity and negative results with metabolic activity. In the SCQ assay using rats, the results suggest that dihydrocapsiate might induce DNA damage in the liver and intestine at an extremely high dose (2000 mg/kg), several factors argue against taking the results of this test at face value. These include (I) the increases observed were quantitatively very small; (2) the assay is known to be highly variable; and (3) it has a high false-positive rate due to apoptosis-induced DNA fragmentation or necrosis with cytotoxicity. Furthermore, no gene mutation was induced in the liver, kidney, and intestine in the 4week repeated oral dose study with transgenic rats, and dihydrocapsiate ingested was not detected in the blood. Therefore, the results of the SCG assay should be viewed within this context.
The similarity of toxicity between commercial and 'laboratory scale' lots of dihydrocapsiate extends beyond the genotoxicity data discussed above. Subchronic rat gavage toxicity studies, 13 weeks in duration, have been performed and reported using both precommercial (Kodama et al. 2008 ) and commercial (Watanabe et al. 2008a ) grades of dihydrocapsiate and the results were within biological variability. The no observed adverse effect levels (NOAELs) from the studies were 1000 and 300 mg/kg/day for the males and 1000 mg/kg/day for the females from both studies in the laboratory scale and commerciallots of dihydrocapsiate, respectively. Both studies identified the liver as the target organ based upon absolute and relative liver weights, and both studies suggested that male rats may be affected more than female rats. The major difference between the studies was that hepatocyte hypertrophy was observed in 2/20 rats (both male) in the Watanabe study (2008a): one slight and one mild. As a result the NOAEL in that study was reduced to 300 mglkg/day.
CONCLUSION
Commercial-grade dihydrocapsiate administered once by gavage to ICR mice at dose levels of 0 (vehicle) or 5000 mg/kg, produced transient signs of acute toxicity observable for 2 h fol-lOWing dosing, but no lethality. Abnormal signs included staggered gait, decreased spontaneous movement, increased time in the prone position, tremors, gasping, or red-brownish urine, all of which were resolved within 6 h of dose administration. No long-term effects or abnormal necropsy findings were observed. The single-dose gavage LD so fordihydrocapsiate in mice of both sexes is >5000 mg/kg.
The evaluation of commercial-grade dihydrocapsiate in an in vivo micronucleus test using BDF, male mice failed to alter the incidences of micronucleated polychromatic erythrocytes (MNPCEs) or the ratios of polychromatic erythrocytes (PCEs) in any of the treatment groups. Based upon the results of this study, commercial-grade dihydrocapsiate is unlikely to be an in vivo clastogen.
